Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06759649 | A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | PHASE1 | RECRUITING | 200 | — | — | Jan 7, 2025 | Nov 22, 2027 | Feb 27, 2026 | 11 | United States, Israel |
Number of participants in monotherapy cohorts with treatment-related adverse events as assessed by CTCAE v4.0
Number of participants in combination cohorts with treatment-related adverse events as assessed by CTCAE v4.
| Arm | Type | Description |
|---|---|---|
| Part 1, A-1 | EXPERIMENTAL | Monotherapy Dose Escalation |
| Part 1, A-2 | EXPERIMENTAL | Backfill |
| Part 1, B | EXPERIMENTAL | Dose escalation, COM503 in combination with a fixed dose of zimberelimab. |
| Part 2, A | EXPERIMENTAL | Dose expansion, COM503 monotherapy |
| Part 2, B | EXPERIMENTAL | Dose expansion, COM503 in combination with a fixed dose of zimberelimab. |
| Name | Type | Description |
|---|---|---|
| COM503 | DRUG | Intravenous Infusion |
| Zimberelimab | DRUG | Intravenous infusion |
Inclusion Criteria: * Participants with histologically/cytologically confirmed advanced recurrent or metastatic solid tumor malignancy * Part 1 (dose escalation): Participants must have had disease progression on or following all available standard of care (SOC) therapies known to confer clinical b...